nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—ABCB1—ovarian cancer	0.28	1	CbGaD
Amsacrine—TOP2A—Epirubicin—ovarian cancer	0.158	0.396	CbGbCtD
Amsacrine—TOP2A—Doxorubicin—ovarian cancer	0.0838	0.21	CbGbCtD
Amsacrine—ABCB1—Topotecan—ovarian cancer	0.042	0.105	CbGbCtD
Amsacrine—ABCB1—Vinorelbine—ovarian cancer	0.0296	0.0743	CbGbCtD
Amsacrine—CYP2D6—Vinorelbine—ovarian cancer	0.0279	0.07	CbGbCtD
Amsacrine—ABCB1—Paclitaxel—ovarian cancer	0.0208	0.0522	CbGbCtD
Amsacrine—ABCB1—Docetaxel—ovarian cancer	0.015	0.0377	CbGbCtD
Amsacrine—ABCB1—Doxorubicin—ovarian cancer	0.0112	0.0281	CbGbCtD
Amsacrine—CYP2D6—Doxorubicin—ovarian cancer	0.0106	0.0265	CbGbCtD
Amsacrine—NCOA3—myometrium—ovarian cancer	0.0041	0.0672	CbGeAlD
Amsacrine—NCOA3—uterine cervix—ovarian cancer	0.00319	0.0523	CbGeAlD
Amsacrine—NCOA3—decidua—ovarian cancer	0.00304	0.0498	CbGeAlD
Amsacrine—NCOA3—endometrium—ovarian cancer	0.00288	0.0473	CbGeAlD
Amsacrine—NCOA3—Irinotecan—Topotecan—ovarian cancer	0.00284	0.474	CbGdCrCtD
Amsacrine—NCOA3—gonad—ovarian cancer	0.00268	0.0438	CbGeAlD
Amsacrine—NCOA3—uterus—ovarian cancer	0.00266	0.0436	CbGeAlD
Amsacrine—TOP2A—myometrium—ovarian cancer	0.0024	0.0394	CbGeAlD
Amsacrine—NCOA3—female reproductive system—ovarian cancer	0.00239	0.0392	CbGeAlD
Amsacrine—NCOA3—bone marrow—ovarian cancer	0.00226	0.037	CbGeAlD
Amsacrine—NCOA3—female gonad—ovarian cancer	0.00217	0.0356	CbGeAlD
Amsacrine—NCOA3—vagina—ovarian cancer	0.00216	0.0354	CbGeAlD
Amsacrine—NCOA3—testis—ovarian cancer	0.00193	0.0316	CbGeAlD
Amsacrine—TOP2A—uterine cervix—ovarian cancer	0.00187	0.0307	CbGeAlD
Amsacrine—TOP2A—decidua—ovarian cancer	0.00178	0.0292	CbGeAlD
Amsacrine—TOP2A—endometrium—ovarian cancer	0.00169	0.0277	CbGeAlD
Amsacrine—TOP2A—uterus—ovarian cancer	0.00156	0.0256	CbGeAlD
Amsacrine—NCOA3—lymph node—ovarian cancer	0.0014	0.0229	CbGeAlD
Amsacrine—KCNH2—myometrium—ovarian cancer	0.00135	0.0221	CbGeAlD
Amsacrine—TOP2A—bone marrow—ovarian cancer	0.00132	0.0217	CbGeAlD
Amsacrine—TOP2A—female gonad—ovarian cancer	0.00128	0.0209	CbGeAlD
Amsacrine—TOP2A—vagina—ovarian cancer	0.00127	0.0208	CbGeAlD
Amsacrine—TOP2A—testis—ovarian cancer	0.00113	0.0185	CbGeAlD
Amsacrine—KCNH2—uterine cervix—ovarian cancer	0.00105	0.0172	CbGeAlD
Amsacrine—KCNH2—endometrium—ovarian cancer	0.000948	0.0155	CbGeAlD
Amsacrine—KCNH2—uterus—ovarian cancer	0.000874	0.0143	CbGeAlD
Amsacrine—TOP2A—lymph node—ovarian cancer	0.00082	0.0134	CbGeAlD
Amsacrine—KCNH2—female reproductive system—ovarian cancer	0.000786	0.0129	CbGeAlD
Amsacrine—KCNH2—bone marrow—ovarian cancer	0.000742	0.0122	CbGeAlD
Amsacrine—KCNH2—female gonad—ovarian cancer	0.000715	0.0117	CbGeAlD
Amsacrine—KCNH2—vagina—ovarian cancer	0.00071	0.0116	CbGeAlD
Amsacrine—KCNH2—testis—ovarian cancer	0.000634	0.0104	CbGeAlD
Amsacrine—ABCB1—myometrium—ovarian cancer	0.000591	0.00968	CbGeAlD
Amsacrine—ABCB1—embryo—ovarian cancer	0.000569	0.00931	CbGeAlD
Amsacrine—NCOA3—Idarubicin—Epirubicin—ovarian cancer	0.000554	0.0926	CbGdCrCtD
Amsacrine—NCOA3—Idarubicin—Doxorubicin—ovarian cancer	0.000513	0.0857	CbGdCrCtD
Amsacrine—CYP2D6—female reproductive system—ovarian cancer	0.000479	0.00785	CbGeAlD
Amsacrine—ABCB1—epithelium—ovarian cancer	0.000464	0.0076	CbGeAlD
Amsacrine—ABCB1—uterine cervix—ovarian cancer	0.00046	0.00754	CbGeAlD
Amsacrine—KCNH2—lymph node—ovarian cancer	0.00046	0.00753	CbGeAlD
Amsacrine—TOP2A—Docetaxel—Paclitaxel—ovarian cancer	0.000455	0.0761	CbGdCrCtD
Amsacrine—ABCB1—decidua—ovarian cancer	0.000438	0.00718	CbGeAlD
Amsacrine—CYP2D6—female gonad—ovarian cancer	0.000436	0.00714	CbGeAlD
Amsacrine—ABCB1—endometrium—ovarian cancer	0.000416	0.00682	CbGeAlD
Amsacrine—TOP2A—Irinotecan—Topotecan—ovarian cancer	0.00039	0.0651	CbGdCrCtD
Amsacrine—CYP2D6—testis—ovarian cancer	0.000387	0.00633	CbGeAlD
Amsacrine—ABCB1—gonad—ovarian cancer	0.000386	0.00632	CbGeAlD
Amsacrine—ABCB1—uterus—ovarian cancer	0.000383	0.00628	CbGeAlD
Amsacrine—ABCB1—female reproductive system—ovarian cancer	0.000345	0.00565	CbGeAlD
Amsacrine—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00034	0.00544	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—MYC—ovarian cancer	0.000335	0.00536	CbGpPWpGaD
Amsacrine—ABCB1—bone marrow—ovarian cancer	0.000325	0.00533	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—ESR1—ovarian cancer	0.000324	0.00519	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—CTNNB1—ovarian cancer	0.000324	0.00518	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CCND1—ovarian cancer	0.000321	0.00513	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—CAV1—ovarian cancer	0.000318	0.00509	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CTNNB1—ovarian cancer	0.000317	0.00508	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—NSF—ovarian cancer	0.000316	0.00505	CbGpPWpGaD
Amsacrine—ABCB1—female gonad—ovarian cancer	0.000314	0.00514	CbGeAlD
Amsacrine—TOP2A—Circadian rythm related genes—HNF1B—ovarian cancer	0.000313	0.00501	CbGpPWpGaD
Amsacrine—ABCB1—vagina—ovarian cancer	0.000312	0.00511	CbGeAlD
Amsacrine—NCOA3—Androgen receptor signaling pathway—PTEN—ovarian cancer	0.000309	0.00495	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.000303	0.00486	CbGpPWpGaD
Amsacrine—TOP2A—Vindesine—Vinorelbine—ovarian cancer	0.000289	0.0484	CbGdCrCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.000289	0.00463	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.000284	0.00455	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—NME2—ovarian cancer	0.000283	0.00454	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	0.000282	0.00451	CbGpPWpGaD
Amsacrine—ABCB1—testis—ovarian cancer	0.000278	0.00456	CbGeAlD
Amsacrine—NCOA3—Androgen receptor signaling pathway—STAT3—ovarian cancer	0.000277	0.00443	CbGpPWpGaD
Amsacrine—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000263	0.00421	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—MYC—ovarian cancer	0.000262	0.0042	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—EGFR—ovarian cancer	0.000256	0.00411	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—EGFR—ovarian cancer	0.000252	0.00403	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.00024	0.00385	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	0.000235	0.00376	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.000233	0.00372	CbGpPWpGaD
Amsacrine—TOP2A—Paclitaxel—Docetaxel—ovarian cancer	0.000227	0.038	CbGdCrCtD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—ovarian cancer	0.000225	0.0036	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—ERBB2—ovarian cancer	0.000225	0.0036	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—MTOR—ovarian cancer	0.000222	0.00355	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.000219	0.00351	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	0.000216	0.00345	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—ovarian cancer	0.000215	0.00345	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	0.00021	0.00336	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	0.000208	0.00333	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000206	0.00329	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.000204	0.00326	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	0.000203	0.00325	CbGpPWpGaD
Amsacrine—ABCB1—lymph node—ovarian cancer	0.000202	0.0033	CbGeAlD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—ovarian cancer	0.000201	0.00322	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.0002	0.0032	CbGpPWpGaD
Amsacrine—Pain—Vinorelbine—ovarian cancer	0.000197	0.00102	CcSEcCtD
Amsacrine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000196	0.00102	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000196	0.00314	CbGpPWpGaD
Amsacrine—Arrhythmia—Paclitaxel—ovarian cancer	0.000195	0.00101	CcSEcCtD
Amsacrine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000195	0.00101	CcSEcCtD
Amsacrine—Hypersensitivity—Melphalan—ovarian cancer	0.000194	0.00101	CcSEcCtD
Amsacrine—Phlebitis—Doxorubicin—ovarian cancer	0.000193	0.00101	CcSEcCtD
Amsacrine—Asthenia—Topotecan—ovarian cancer	0.000193	0.00101	CcSEcCtD
Amsacrine—Alopecia—Paclitaxel—ovarian cancer	0.000193	0.001	CcSEcCtD
Amsacrine—Vomiting—Chlorambucil—ovarian cancer	0.000192	0.001	CcSEcCtD
Amsacrine—Agranulocytosis—Docetaxel—ovarian cancer	0.000192	0.001	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—PTEN—ovarian cancer	0.000192	0.00307	CbGpPWpGaD
Amsacrine—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.000192	0.000997	CcSEcCtD
Amsacrine—Mental disorder—Paclitaxel—ovarian cancer	0.000191	0.000994	CcSEcCtD
Amsacrine—Malnutrition—Paclitaxel—ovarian cancer	0.00019	0.000988	CcSEcCtD
Amsacrine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00019	0.000987	CcSEcCtD
Amsacrine—Asthenia—Melphalan—ovarian cancer	0.000189	0.000984	CcSEcCtD
Amsacrine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000188	0.00098	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000188	0.00301	CbGpPWpGaD
Amsacrine—Purpura—Epirubicin—ovarian cancer	0.000187	0.000973	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—RAD51C—ovarian cancer	0.000186	0.00298	CbGpPWpGaD
Amsacrine—Vascular purpura—Doxorubicin—ovarian cancer	0.000186	0.00097	CcSEcCtD
Amsacrine—Haemoglobin—Docetaxel—ovarian cancer	0.000186	0.000966	CcSEcCtD
Amsacrine—Hepatic failure—Doxorubicin—ovarian cancer	0.000185	0.000965	CcSEcCtD
Amsacrine—Hepatitis—Docetaxel—ovarian cancer	0.000185	0.000962	CcSEcCtD
Amsacrine—Haemorrhage—Docetaxel—ovarian cancer	0.000185	0.000962	CcSEcCtD
Amsacrine—Diarrhoea—Topotecan—ovarian cancer	0.000184	0.000958	CcSEcCtD
Amsacrine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000184	0.000957	CcSEcCtD
Amsacrine—Lethargy—Epirubicin—ovarian cancer	0.000184	0.000957	CcSEcCtD
Amsacrine—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000184	0.000957	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	0.000183	0.00293	CbGpPWpGaD
Amsacrine—Urticaria—Vinorelbine—ovarian cancer	0.000183	0.000952	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CYTB—ovarian cancer	0.000183	0.00292	CbGpPWpGaD
Amsacrine—Urinary tract disorder—Docetaxel—ovarian cancer	0.000182	0.00095	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.000182	0.00292	CbGpPWpGaD
Amsacrine—Body temperature increased—Vinorelbine—ovarian cancer	0.000182	0.000947	CcSEcCtD
Amsacrine—Abdominal pain—Vinorelbine—ovarian cancer	0.000182	0.000947	CcSEcCtD
Amsacrine—Connective tissue disorder—Docetaxel—ovarian cancer	0.000181	0.000945	CcSEcCtD
Amsacrine—Urethral disorder—Docetaxel—ovarian cancer	0.000181	0.000943	CcSEcCtD
Amsacrine—Diarrhoea—Melphalan—ovarian cancer	0.00018	0.000938	CcSEcCtD
Amsacrine—Nausea—Chlorambucil—ovarian cancer	0.00018	0.000935	CcSEcCtD
Amsacrine—Vision blurred—Paclitaxel—ovarian cancer	0.000179	0.000931	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000178	0.00286	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—AKT1—ovarian cancer	0.000178	0.00286	CbGpPWpGaD
Amsacrine—Dizziness—Topotecan—ovarian cancer	0.000178	0.000926	CcSEcCtD
Amsacrine—Affect lability—Epirubicin—ovarian cancer	0.000177	0.000923	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000176	0.00282	CbGpPWpGaD
Amsacrine—Anaemia—Paclitaxel—ovarian cancer	0.000175	0.000913	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000174	0.00278	CbGpPWpGaD
Amsacrine—Purpura—Doxorubicin—ovarian cancer	0.000173	0.0009	CcSEcCtD
Amsacrine—Cardiac disorder—Docetaxel—ovarian cancer	0.000171	0.000892	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—STAT3—ovarian cancer	0.000171	0.00274	CbGpPWpGaD
Amsacrine—Vomiting—Topotecan—ovarian cancer	0.000171	0.000891	CcSEcCtD
Amsacrine—Mood swings—Epirubicin—ovarian cancer	0.000171	0.000888	CcSEcCtD
Amsacrine—Lethargy—Doxorubicin—ovarian cancer	0.00017	0.000885	CcSEcCtD
Amsacrine—Leukopenia—Paclitaxel—ovarian cancer	0.00017	0.000884	CcSEcCtD
Amsacrine—Rash—Topotecan—ovarian cancer	0.00017	0.000883	CcSEcCtD
Amsacrine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00017	0.000883	CcSEcCtD
Amsacrine—Dermatitis—Topotecan—ovarian cancer	0.000169	0.000882	CcSEcCtD
Amsacrine—Blood creatinine increased—Epirubicin—ovarian cancer	0.000169	0.000878	CcSEcCtD
Amsacrine—Headache—Topotecan—ovarian cancer	0.000169	0.000878	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MYC—ovarian cancer	0.000168	0.0027	CbGpPWpGaD
Amsacrine—Angiopathy—Docetaxel—ovarian cancer	0.000168	0.000872	CcSEcCtD
Amsacrine—Vomiting—Melphalan—ovarian cancer	0.000167	0.000872	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000167	0.00268	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Docetaxel—ovarian cancer	0.000166	0.000867	CcSEcCtD
Amsacrine—Rash—Melphalan—ovarian cancer	0.000166	0.000865	CcSEcCtD
Amsacrine—Dermatitis—Melphalan—ovarian cancer	0.000166	0.000864	CcSEcCtD
Amsacrine—Asthenia—Vinorelbine—ovarian cancer	0.000165	0.00086	CcSEcCtD
Amsacrine—Arrhythmia—Docetaxel—ovarian cancer	0.000165	0.000859	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	0.000165	0.00264	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	0.000165	0.00264	CbGpPWpGaD
Amsacrine—Convulsion—Paclitaxel—ovarian cancer	0.000164	0.000856	CcSEcCtD
Amsacrine—Affect lability—Doxorubicin—ovarian cancer	0.000164	0.000854	CcSEcCtD
Amsacrine—Alopecia—Docetaxel—ovarian cancer	0.000163	0.00085	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—PPP1CC—ovarian cancer	0.000163	0.00261	CbGpPWpGaD
Amsacrine—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000162	0.000844	CcSEcCtD
Amsacrine—Mental disorder—Docetaxel—ovarian cancer	0.000162	0.000842	CcSEcCtD
Amsacrine—Malnutrition—Docetaxel—ovarian cancer	0.000161	0.000837	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00016	0.000835	CcSEcCtD
Amsacrine—Nausea—Topotecan—ovarian cancer	0.00016	0.000832	CcSEcCtD
Amsacrine—NCOA3—Metabolism—BRIP1—ovarian cancer	0.00016	0.00256	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PPP1CC—ovarian cancer	0.00016	0.00256	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000159	0.00255	CbGpPWpGaD
Amsacrine—Mood swings—Doxorubicin—ovarian cancer	0.000158	0.000822	CcSEcCtD
Amsacrine—Diarrhoea—Vinorelbine—ovarian cancer	0.000157	0.00082	CcSEcCtD
Amsacrine—Nausea—Melphalan—ovarian cancer	0.000156	0.000815	CcSEcCtD
Amsacrine—TOP2A—Vincristine—Vinorelbine—ovarian cancer	0.000156	0.0261	CbGdCrCtD
Amsacrine—Confusional state—Paclitaxel—ovarian cancer	0.000156	0.000813	CcSEcCtD
Amsacrine—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000156	0.000813	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—MAPK1—ovarian cancer	0.000156	0.00249	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—EGFR—ovarian cancer	0.000156	0.00249	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	0.000156	0.00249	CbGpPWpGaD
Amsacrine—Dysphagia—Epirubicin—ovarian cancer	0.000156	0.00081	CcSEcCtD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—ovarian cancer	0.000155	0.00248	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000154	0.00247	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000154	0.00247	CbGpPWpGaD
Amsacrine—Infection—Paclitaxel—ovarian cancer	0.000154	0.000801	CcSEcCtD
Amsacrine—Dizziness—Vinorelbine—ovarian cancer	0.000152	0.000792	CcSEcCtD
Amsacrine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000152	0.000789	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000152	0.00243	CbGpPWpGaD
Amsacrine—Tachycardia—Paclitaxel—ovarian cancer	0.000151	0.000787	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—ovarian cancer	0.000151	0.00241	CbGpPWpGaD
Amsacrine—Skin disorder—Paclitaxel—ovarian cancer	0.00015	0.000783	CcSEcCtD
Amsacrine—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.00015	0.000781	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.00015	0.0024	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—RBL2—ovarian cancer	0.00015	0.00239	CbGpPWpGaD
Amsacrine—Anaemia—Docetaxel—ovarian cancer	0.000149	0.000774	CcSEcCtD
Amsacrine—Pancytopenia—Epirubicin—ovarian cancer	0.000148	0.00077	CcSEcCtD
Amsacrine—Anorexia—Paclitaxel—ovarian cancer	0.000148	0.000768	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—KRAS—ovarian cancer	0.000147	0.00236	CbGpPWpGaD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000147	0.00235	CbGpPWpGaD
Amsacrine—Vomiting—Vinorelbine—ovarian cancer	0.000146	0.000762	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—TYMS—ovarian cancer	0.000145	0.00233	CbGpPWpGaD
Amsacrine—Rash—Vinorelbine—ovarian cancer	0.000145	0.000756	CcSEcCtD
Amsacrine—Dermatitis—Vinorelbine—ovarian cancer	0.000145	0.000755	CcSEcCtD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000145	0.00232	CbGpPWpGaD
Amsacrine—Hypotension—Paclitaxel—ovarian cancer	0.000145	0.000753	CcSEcCtD
Amsacrine—Headache—Vinorelbine—ovarian cancer	0.000144	0.000751	CcSEcCtD
Amsacrine—Dysphagia—Doxorubicin—ovarian cancer	0.000144	0.00075	CcSEcCtD
Amsacrine—Leukopenia—Docetaxel—ovarian cancer	0.000144	0.000749	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000143	0.00229	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000142	0.00227	CbGpPWpGaD
Amsacrine—Weight increased—Epirubicin—ovarian cancer	0.000142	0.000737	CcSEcCtD
Amsacrine—Weight decreased—Epirubicin—ovarian cancer	0.000141	0.000733	CcSEcCtD
Amsacrine—Convulsion—Docetaxel—ovarian cancer	0.000139	0.000725	CcSEcCtD
Amsacrine—Paraesthesia—Paclitaxel—ovarian cancer	0.000139	0.000724	CcSEcCtD
Amsacrine—Infestation—Epirubicin—ovarian cancer	0.000139	0.000722	CcSEcCtD
Amsacrine—Infestation NOS—Epirubicin—ovarian cancer	0.000139	0.000722	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—ovarian cancer	0.000138	0.00222	CbGpPWpGaD
Amsacrine—Dyspnoea—Paclitaxel—ovarian cancer	0.000138	0.000719	CcSEcCtD
Amsacrine—Pancytopenia—Doxorubicin—ovarian cancer	0.000137	0.000712	CcSEcCtD
Amsacrine—Nausea—Vinorelbine—ovarian cancer	0.000137	0.000712	CcSEcCtD
Amsacrine—Renal failure—Epirubicin—ovarian cancer	0.000136	0.00071	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000136	0.000708	CcSEcCtD
Amsacrine—Stomatitis—Epirubicin—ovarian cancer	0.000135	0.000704	CcSEcCtD
Amsacrine—Jaundice—Epirubicin—ovarian cancer	0.000135	0.000704	CcSEcCtD
Amsacrine—Decreased appetite—Paclitaxel—ovarian cancer	0.000135	0.000701	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000134	0.000696	CcSEcCtD
Amsacrine—Fatigue—Paclitaxel—ovarian cancer	0.000133	0.000695	CcSEcCtD
Amsacrine—Pain—Paclitaxel—ovarian cancer	0.000132	0.000689	CcSEcCtD
Amsacrine—Haematuria—Epirubicin—ovarian cancer	0.000132	0.000689	CcSEcCtD
Amsacrine—Confusional state—Docetaxel—ovarian cancer	0.000132	0.000689	CcSEcCtD
Amsacrine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000131	0.000683	CcSEcCtD
Amsacrine—Weight increased—Doxorubicin—ovarian cancer	0.000131	0.000682	CcSEcCtD
Amsacrine—Infection—Docetaxel—ovarian cancer	0.00013	0.000679	CcSEcCtD
Amsacrine—Weight decreased—Doxorubicin—ovarian cancer	0.00013	0.000678	CcSEcCtD
Amsacrine—Agranulocytosis—Epirubicin—ovarian cancer	0.000129	0.000674	CcSEcCtD
Amsacrine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000128	0.000669	CcSEcCtD
Amsacrine—Infestation—Doxorubicin—ovarian cancer	0.000128	0.000668	CcSEcCtD
Amsacrine—Infestation NOS—Doxorubicin—ovarian cancer	0.000128	0.000668	CcSEcCtD
Amsacrine—Tachycardia—Docetaxel—ovarian cancer	0.000128	0.000667	CcSEcCtD
Amsacrine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000128	0.000664	CcSEcCtD
Amsacrine—Skin disorder—Docetaxel—ovarian cancer	0.000127	0.000664	CcSEcCtD
Amsacrine—Bradycardia—Epirubicin—ovarian cancer	0.000127	0.00066	CcSEcCtD
Amsacrine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000127	0.000659	CcSEcCtD
Amsacrine—Renal failure—Doxorubicin—ovarian cancer	0.000126	0.000657	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—MET—ovarian cancer	0.000126	0.00202	CbGpPWpGaD
Amsacrine—TOP2A—Vinblastine—Vinorelbine—ovarian cancer	0.000126	0.021	CbGdCrCtD
Amsacrine—Haemoglobin—Epirubicin—ovarian cancer	0.000125	0.000652	CcSEcCtD
Amsacrine—Stomatitis—Doxorubicin—ovarian cancer	0.000125	0.000652	CcSEcCtD
Amsacrine—Jaundice—Doxorubicin—ovarian cancer	0.000125	0.000652	CcSEcCtD
Amsacrine—Anorexia—Docetaxel—ovarian cancer	0.000125	0.000651	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—HRAS—ovarian cancer	0.000125	0.002	CbGpPWpGaD
Amsacrine—Hepatitis—Epirubicin—ovarian cancer	0.000125	0.000649	CcSEcCtD
Amsacrine—Haemorrhage—Epirubicin—ovarian cancer	0.000125	0.000649	CcSEcCtD
Amsacrine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000124	0.000645	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—IL6ST—ovarian cancer	0.000123	0.00198	CbGpPWpGaD
Amsacrine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000123	0.000641	CcSEcCtD
Amsacrine—Urticaria—Paclitaxel—ovarian cancer	0.000123	0.00064	CcSEcCtD
Amsacrine—Hypotension—Docetaxel—ovarian cancer	0.000123	0.000638	CcSEcCtD
Amsacrine—Haematuria—Doxorubicin—ovarian cancer	0.000122	0.000637	CcSEcCtD
Amsacrine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000122	0.000637	CcSEcCtD
Amsacrine—Abdominal pain—Paclitaxel—ovarian cancer	0.000122	0.000637	CcSEcCtD
Amsacrine—Body temperature increased—Paclitaxel—ovarian cancer	0.000122	0.000637	CcSEcCtD
Amsacrine—Urethral disorder—Epirubicin—ovarian cancer	0.000122	0.000636	CcSEcCtD
Amsacrine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000121	0.000632	CcSEcCtD
Amsacrine—Agranulocytosis—Doxorubicin—ovarian cancer	0.00012	0.000624	CcSEcCtD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000119	0.00191	CbGpPWpGaD
Amsacrine—Paraesthesia—Docetaxel—ovarian cancer	0.000118	0.000613	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000118	0.00188	CbGpPWpGaD
Amsacrine—Bradycardia—Doxorubicin—ovarian cancer	0.000117	0.000611	CcSEcCtD
Amsacrine—Dyspnoea—Docetaxel—ovarian cancer	0.000117	0.000609	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	0.000117	0.00187	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000116	0.00186	CbGpPWpGaD
Amsacrine—Haemoglobin—Doxorubicin—ovarian cancer	0.000116	0.000603	CcSEcCtD
Amsacrine—Cardiac disorder—Epirubicin—ovarian cancer	0.000116	0.000602	CcSEcCtD
Amsacrine—Haemorrhage—Doxorubicin—ovarian cancer	0.000115	0.0006	CcSEcCtD
Amsacrine—Hepatitis—Doxorubicin—ovarian cancer	0.000115	0.0006	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000115	0.00184	CbGpPWpGaD
Amsacrine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000115	0.000597	CcSEcCtD
Amsacrine—Decreased appetite—Docetaxel—ovarian cancer	0.000114	0.000594	CcSEcCtD
Amsacrine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000114	0.000594	CcSEcCtD
Amsacrine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000114	0.000593	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000113	0.00059	CcSEcCtD
Amsacrine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000113	0.00059	CcSEcCtD
Amsacrine—Fatigue—Docetaxel—ovarian cancer	0.000113	0.000589	CcSEcCtD
Amsacrine—Angiopathy—Epirubicin—ovarian cancer	0.000113	0.000588	CcSEcCtD
Amsacrine—Urethral disorder—Doxorubicin—ovarian cancer	0.000113	0.000588	CcSEcCtD
Amsacrine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000112	0.000585	CcSEcCtD
Amsacrine—Pain—Docetaxel—ovarian cancer	0.000112	0.000584	CcSEcCtD
Amsacrine—Arrhythmia—Epirubicin—ovarian cancer	0.000111	0.000579	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000111	0.00178	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000111	0.00178	CbGpPWpGaD
Amsacrine—Asthenia—Paclitaxel—ovarian cancer	0.000111	0.000578	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—AKT1—ovarian cancer	0.00011	0.00177	CbGpPWpGaD
Amsacrine—Alopecia—Epirubicin—ovarian cancer	0.00011	0.000573	CcSEcCtD
Amsacrine—Mental disorder—Epirubicin—ovarian cancer	0.000109	0.000568	CcSEcCtD
Amsacrine—Malnutrition—Epirubicin—ovarian cancer	0.000108	0.000565	CcSEcCtD
Amsacrine—Feeling abnormal—Docetaxel—ovarian cancer	0.000108	0.000563	CcSEcCtD
Amsacrine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000107	0.000559	CcSEcCtD
Amsacrine—NCOA3—Metabolism—YAP1—ovarian cancer	0.000107	0.00171	CbGpPWpGaD
Amsacrine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000107	0.000557	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	0.000106	0.0017	CbGpPWpGaD
Amsacrine—Diarrhoea—Paclitaxel—ovarian cancer	0.000106	0.000551	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000106	0.00169	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—MMP2—ovarian cancer	0.000105	0.00168	CbGpPWpGaD
Amsacrine—Angiopathy—Doxorubicin—ovarian cancer	0.000105	0.000544	CcSEcCtD
Amsacrine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000104	0.000541	CcSEcCtD
Amsacrine—Body temperature increased—Docetaxel—ovarian cancer	0.000104	0.00054	CcSEcCtD
Amsacrine—Abdominal pain—Docetaxel—ovarian cancer	0.000104	0.00054	CcSEcCtD
Amsacrine—Arrhythmia—Doxorubicin—ovarian cancer	0.000103	0.000536	CcSEcCtD
Amsacrine—Dizziness—Paclitaxel—ovarian cancer	0.000102	0.000533	CcSEcCtD
Amsacrine—Vision blurred—Epirubicin—ovarian cancer	0.000102	0.000532	CcSEcCtD
Amsacrine—Alopecia—Doxorubicin—ovarian cancer	0.000102	0.00053	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—TERT—ovarian cancer	0.000102	0.00163	CbGpPWpGaD
Amsacrine—Mental disorder—Doxorubicin—ovarian cancer	0.000101	0.000526	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000101	0.00161	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MLH1—ovarian cancer	0.000101	0.00161	CbGpPWpGaD
Amsacrine—Malnutrition—Doxorubicin—ovarian cancer	0.0001	0.000522	CcSEcCtD
Amsacrine—Anaemia—Epirubicin—ovarian cancer	0.0001	0.000522	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—SKP2—ovarian cancer	9.95e-05	0.00159	CbGpPWpGaD
Amsacrine—Vomiting—Paclitaxel—ovarian cancer	9.84e-05	0.000512	CcSEcCtD
Amsacrine—Rash—Paclitaxel—ovarian cancer	9.76e-05	0.000508	CcSEcCtD
Amsacrine—Dermatitis—Paclitaxel—ovarian cancer	9.75e-05	0.000508	CcSEcCtD
Amsacrine—Leukopenia—Epirubicin—ovarian cancer	9.71e-05	0.000505	CcSEcCtD
Amsacrine—Headache—Paclitaxel—ovarian cancer	9.7e-05	0.000505	CcSEcCtD
Amsacrine—Hypersensitivity—Docetaxel—ovarian cancer	9.67e-05	0.000503	CcSEcCtD
Amsacrine—Vision blurred—Doxorubicin—ovarian cancer	9.46e-05	0.000492	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	9.43e-05	0.00151	CbGpPWpGaD
Amsacrine—Asthenia—Docetaxel—ovarian cancer	9.41e-05	0.00049	CcSEcCtD
Amsacrine—Convulsion—Epirubicin—ovarian cancer	9.4e-05	0.000489	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.31e-05	0.00149	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	9.3e-05	0.00149	CbGpPWpGaD
Amsacrine—Anaemia—Doxorubicin—ovarian cancer	9.27e-05	0.000483	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—ERBB2—ovarian cancer	9.21e-05	0.00147	CbGpPWpGaD
Amsacrine—Nausea—Paclitaxel—ovarian cancer	9.19e-05	0.000479	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	9.17e-05	0.000477	CcSEcCtD
Amsacrine—Leukopenia—Doxorubicin—ovarian cancer	8.98e-05	0.000468	CcSEcCtD
Amsacrine—Diarrhoea—Docetaxel—ovarian cancer	8.98e-05	0.000467	CcSEcCtD
Amsacrine—Confusional state—Epirubicin—ovarian cancer	8.92e-05	0.000465	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CASP3—ovarian cancer	8.9e-05	0.00143	CbGpPWpGaD
Amsacrine—Infection—Epirubicin—ovarian cancer	8.79e-05	0.000458	CcSEcCtD
Amsacrine—NCOA3—Metabolism—FASN—ovarian cancer	8.73e-05	0.0014	CbGpPWpGaD
Amsacrine—Convulsion—Doxorubicin—ovarian cancer	8.69e-05	0.000453	CcSEcCtD
Amsacrine—Dizziness—Docetaxel—ovarian cancer	8.68e-05	0.000452	CcSEcCtD
Amsacrine—Thrombocytopenia—Epirubicin—ovarian cancer	8.67e-05	0.000451	CcSEcCtD
Amsacrine—Tachycardia—Epirubicin—ovarian cancer	8.64e-05	0.00045	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	8.64e-05	0.00138	CbGpPWpGaD
Amsacrine—Skin disorder—Epirubicin—ovarian cancer	8.6e-05	0.000448	CcSEcCtD
Amsacrine—NCOA3—Metabolism—SLC5A5—ovarian cancer	8.58e-05	0.00137	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	8.58e-05	0.00137	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCND2—ovarian cancer	8.53e-05	0.00137	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	8.48e-05	0.000442	CcSEcCtD
Amsacrine—Anorexia—Epirubicin—ovarian cancer	8.44e-05	0.000439	CcSEcCtD
Amsacrine—Vomiting—Docetaxel—ovarian cancer	8.34e-05	0.000434	CcSEcCtD
Amsacrine—NCOA3—Metabolism—SLC2A1—ovarian cancer	8.29e-05	0.00133	CbGpPWpGaD
Amsacrine—Rash—Docetaxel—ovarian cancer	8.27e-05	0.000431	CcSEcCtD
Amsacrine—Hypotension—Epirubicin—ovarian cancer	8.27e-05	0.000431	CcSEcCtD
Amsacrine—Dermatitis—Docetaxel—ovarian cancer	8.27e-05	0.00043	CcSEcCtD
Amsacrine—Confusional state—Doxorubicin—ovarian cancer	8.26e-05	0.00043	CcSEcCtD
Amsacrine—Headache—Docetaxel—ovarian cancer	8.22e-05	0.000428	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—CHEK2—ovarian cancer	8.14e-05	0.0013	CbGpPWpGaD
Amsacrine—Infection—Doxorubicin—ovarian cancer	8.14e-05	0.000424	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.12e-05	0.0013	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—MYC—ovarian cancer	8.08e-05	0.00129	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—CTNNB1—ovarian cancer	8.06e-05	0.00129	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	8.04e-05	0.00129	CbGpPWpGaD
Amsacrine—Thrombocytopenia—Doxorubicin—ovarian cancer	8.02e-05	0.000417	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	8e-05	0.00128	CbGpPWpGaD
Amsacrine—Tachycardia—Doxorubicin—ovarian cancer	7.99e-05	0.000416	CcSEcCtD
Amsacrine—Skin disorder—Doxorubicin—ovarian cancer	7.95e-05	0.000414	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CYP1B1—ovarian cancer	7.95e-05	0.00127	CbGpPWpGaD
Amsacrine—Paraesthesia—Epirubicin—ovarian cancer	7.95e-05	0.000414	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—MMP9—ovarian cancer	7.9e-05	0.00126	CbGpPWpGaD
Amsacrine—Dyspnoea—Epirubicin—ovarian cancer	7.89e-05	0.000411	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	7.84e-05	0.00126	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	7.82e-05	0.00125	CbGpPWpGaD
Amsacrine—Anorexia—Doxorubicin—ovarian cancer	7.81e-05	0.000406	CcSEcCtD
Amsacrine—Nausea—Docetaxel—ovarian cancer	7.79e-05	0.000406	CcSEcCtD
Amsacrine—Decreased appetite—Epirubicin—ovarian cancer	7.69e-05	0.000401	CcSEcCtD
Amsacrine—Hypotension—Doxorubicin—ovarian cancer	7.65e-05	0.000398	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Epirubicin—ovarian cancer	7.64e-05	0.000398	CcSEcCtD
Amsacrine—Fatigue—Epirubicin—ovarian cancer	7.63e-05	0.000397	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	7.63e-05	0.00122	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCND2—ovarian cancer	7.63e-05	0.00122	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—BRCA1—ovarian cancer	7.63e-05	0.00122	CbGpPWpGaD
Amsacrine—TOP2A—Idarubicin—Epirubicin—ovarian cancer	7.61e-05	0.0127	CbGdCrCtD
Amsacrine—TOP2A—Doxorubicin—Epirubicin—ovarian cancer	7.61e-05	0.0127	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Epirubicin—ovarian cancer	7.61e-05	0.0127	CbGdCrCtD
Amsacrine—Pain—Epirubicin—ovarian cancer	7.57e-05	0.000394	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	7.56e-05	0.00121	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	7.55e-05	0.00121	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCNE1—ovarian cancer	7.47e-05	0.0012	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	7.36e-05	0.00118	CbGpPWpGaD
Amsacrine—Paraesthesia—Doxorubicin—ovarian cancer	7.35e-05	0.000383	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—TYMS—ovarian cancer	7.34e-05	0.00117	CbGpPWpGaD
Amsacrine—Dyspnoea—Doxorubicin—ovarian cancer	7.3e-05	0.00038	CcSEcCtD
Amsacrine—Feeling abnormal—Epirubicin—ovarian cancer	7.29e-05	0.00038	CcSEcCtD
Amsacrine—Gastrointestinal pain—Epirubicin—ovarian cancer	7.24e-05	0.000377	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—PPP2R1A—ovarian cancer	7.19e-05	0.00115	CbGpPWpGaD
Amsacrine—Decreased appetite—Doxorubicin—ovarian cancer	7.12e-05	0.000371	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—VEGFA—ovarian cancer	7.09e-05	0.00114	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	7.07e-05	0.000368	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PTEN—ovarian cancer	7.07e-05	0.00113	CbGpPWpGaD
Amsacrine—Fatigue—Doxorubicin—ovarian cancer	7.06e-05	0.000368	CcSEcCtD
Amsacrine—NCOA3—Metabolism—PPP2R1A—ovarian cancer	7.05e-05	0.00113	CbGpPWpGaD
Amsacrine—TOP2A—Epirubicin—Doxorubicin—ovarian cancer	7.04e-05	0.0118	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Doxorubicin—ovarian cancer	7.04e-05	0.0118	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Doxorubicin—ovarian cancer	7.04e-05	0.0118	CbGdCrCtD
Amsacrine—Urticaria—Epirubicin—ovarian cancer	7.03e-05	0.000366	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—STAT3—ovarian cancer	7.02e-05	0.00112	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.01e-05	0.00112	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—NRAS—ovarian cancer	7.01e-05	0.00112	CbGpPWpGaD
Amsacrine—Pain—Doxorubicin—ovarian cancer	7e-05	0.000365	CcSEcCtD
Amsacrine—Body temperature increased—Epirubicin—ovarian cancer	7e-05	0.000364	CcSEcCtD
Amsacrine—Abdominal pain—Epirubicin—ovarian cancer	7e-05	0.000364	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—BRCA2—ovarian cancer	6.9e-05	0.0011	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	6.77e-05	0.00108	CbGpPWpGaD
Amsacrine—Feeling abnormal—Doxorubicin—ovarian cancer	6.75e-05	0.000351	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—MAPK3—ovarian cancer	6.71e-05	0.00107	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Doxorubicin—ovarian cancer	6.7e-05	0.000349	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—CCNE1—ovarian cancer	6.68e-05	0.00107	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	6.65e-05	0.00107	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—BIRC5—ovarian cancer	6.6e-05	0.00106	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TYMS—ovarian cancer	6.56e-05	0.00105	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—ABCB1—ovarian cancer	6.54e-05	0.00105	CbGpPWpGaD
Amsacrine—Hypersensitivity—Epirubicin—ovarian cancer	6.52e-05	0.000339	CcSEcCtD
Amsacrine—Urticaria—Doxorubicin—ovarian cancer	6.51e-05	0.000339	CcSEcCtD
Amsacrine—Abdominal pain—Doxorubicin—ovarian cancer	6.47e-05	0.000337	CcSEcCtD
Amsacrine—Body temperature increased—Doxorubicin—ovarian cancer	6.47e-05	0.000337	CcSEcCtD
Amsacrine—NCOA3—Metabolism—TYMS—ovarian cancer	6.43e-05	0.00103	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—MAPK1—ovarian cancer	6.38e-05	0.00102	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—EGFR—ovarian cancer	6.38e-05	0.00102	CbGpPWpGaD
Amsacrine—Asthenia—Epirubicin—ovarian cancer	6.35e-05	0.000331	CcSEcCtD
Amsacrine—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	6.32e-05	0.00101	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	6.29e-05	0.00101	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	6.24e-05	0.000998	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	6.19e-05	0.000991	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	6.12e-05	0.00098	CbGpPWpGaD
Amsacrine—Diarrhoea—Epirubicin—ovarian cancer	6.06e-05	0.000315	CcSEcCtD
Amsacrine—Hypersensitivity—Doxorubicin—ovarian cancer	6.03e-05	0.000314	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—KRAS—ovarian cancer	6.03e-05	0.000966	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	5.99e-05	0.000959	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	5.99e-05	0.000958	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	5.98e-05	0.000958	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—BIRC5—ovarian cancer	5.9e-05	0.000945	CbGpPWpGaD
Amsacrine—Asthenia—Doxorubicin—ovarian cancer	5.88e-05	0.000306	CcSEcCtD
Amsacrine—Dizziness—Epirubicin—ovarian cancer	5.85e-05	0.000305	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	5.8e-05	0.000929	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TERT—ovarian cancer	5.71e-05	0.000915	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	5.65e-05	0.000905	CbGpPWpGaD
Amsacrine—Vomiting—Epirubicin—ovarian cancer	5.63e-05	0.000293	CcSEcCtD
Amsacrine—Diarrhoea—Doxorubicin—ovarian cancer	5.6e-05	0.000292	CcSEcCtD
Amsacrine—Rash—Epirubicin—ovarian cancer	5.58e-05	0.000291	CcSEcCtD
Amsacrine—Dermatitis—Epirubicin—ovarian cancer	5.57e-05	0.00029	CcSEcCtD
Amsacrine—Headache—Epirubicin—ovarian cancer	5.54e-05	0.000289	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	5.46e-05	0.000875	CbGpPWpGaD
Amsacrine—Dizziness—Doxorubicin—ovarian cancer	5.42e-05	0.000282	CcSEcCtD
Amsacrine—Nausea—Epirubicin—ovarian cancer	5.26e-05	0.000274	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	5.25e-05	0.00084	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	5.23e-05	0.000838	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—CASP3—ovarian cancer	5.23e-05	0.000837	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—IL6—ovarian cancer	5.22e-05	0.000836	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—IL2—ovarian cancer	5.22e-05	0.000836	CbGpPWpGaD
Amsacrine—Vomiting—Doxorubicin—ovarian cancer	5.21e-05	0.000271	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	5.2e-05	0.000832	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CAV1—ovarian cancer	5.18e-05	0.000829	CbGpPWpGaD
Amsacrine—Rash—Doxorubicin—ovarian cancer	5.16e-05	0.000269	CcSEcCtD
Amsacrine—Dermatitis—Doxorubicin—ovarian cancer	5.16e-05	0.000269	CcSEcCtD
Amsacrine—Headache—Doxorubicin—ovarian cancer	5.13e-05	0.000267	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—HRAS—ovarian cancer	5.13e-05	0.000821	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	5.12e-05	0.000821	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	5.08e-05	0.000814	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	5.03e-05	0.000805	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.02e-05	0.000803	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	4.99e-05	0.000799	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.95e-05	0.000792	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—IL6—ovarian cancer	4.91e-05	0.000786	CbGpPWpGaD
Amsacrine—Nausea—Doxorubicin—ovarian cancer	4.86e-05	0.000253	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—ovarian cancer	4.82e-05	0.000773	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PIK3CG—ovarian cancer	4.72e-05	0.000755	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—AKT1—ovarian cancer	4.53e-05	0.000725	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	4.44e-05	0.000711	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—IL6—ovarian cancer	4.42e-05	0.000707	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—MAPK1—ovarian cancer	4.27e-05	0.000684	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.24e-05	0.00068	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PIK3CD—ovarian cancer	4.15e-05	0.000664	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NME2—ovarian cancer	4.09e-05	0.000655	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.96e-05	0.000635	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	3.87e-05	0.00062	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	3.87e-05	0.00062	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NME2—ovarian cancer	3.85e-05	0.000617	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCND1—ovarian cancer	3.69e-05	0.000591	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	3.66e-05	0.000586	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PIK3CB—ovarian cancer	3.61e-05	0.000579	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN1B—ovarian cancer	3.46e-05	0.000554	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—HRAS—ovarian cancer	3.43e-05	0.000549	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCND1—ovarian cancer	3.3e-05	0.000529	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	3.27e-05	0.000524	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTEN—ovarian cancer	3.12e-05	0.0005	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—MAPK3—ovarian cancer	3.05e-05	0.000488	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—MYC—ovarian cancer	2.96e-05	0.000474	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—MAPK1—ovarian cancer	2.9e-05	0.000464	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.84e-05	0.000455	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MAPK3—ovarian cancer	2.72e-05	0.000436	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MYC—ovarian cancer	2.65e-05	0.000424	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.65e-05	0.000424	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYTB—ovarian cancer	2.64e-05	0.000422	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.63e-05	0.000422	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MAPK1—ovarian cancer	2.59e-05	0.000415	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.58e-05	0.000413	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.55e-05	0.000409	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.51e-05	0.000402	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.49e-05	0.000398	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYTB—ovarian cancer	2.48e-05	0.000398	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.42e-05	0.000388	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—BRIP1—ovarian cancer	2.3e-05	0.000369	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.3e-05	0.000369	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PIK3CA—ovarian cancer	2.2e-05	0.000353	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.19e-05	0.000351	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—ovarian cancer	2.18e-05	0.000348	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.17e-05	0.000348	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.17e-05	0.000348	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.07e-05	0.000332	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.02e-05	0.000323	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.97e-05	0.000316	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.97e-05	0.000316	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.86e-05	0.000298	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—AKT1—ovarian cancer	1.8e-05	0.000288	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.71e-05	0.000274	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.65e-05	0.000265	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—YAP1—ovarian cancer	1.55e-05	0.000247	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—YAP1—ovarian cancer	1.46e-05	0.000233	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.4e-05	0.000224	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—FASN—ovarian cancer	1.26e-05	0.000202	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.24e-05	0.000198	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.2e-05	0.000192	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—FASN—ovarian cancer	1.19e-05	0.00019	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.17e-05	0.000187	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.15e-05	0.000184	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.13e-05	0.000181	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.08e-05	0.000173	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.02e-05	0.000163	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.59e-06	0.000154	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—TYMS—ovarian cancer	9.28e-06	0.000149	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ABCB1—ovarian cancer	8.9e-06	0.000143	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—TYMS—ovarian cancer	8.74e-06	0.00014	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CAV1—ovarian cancer	7.48e-06	0.00012	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CAV1—ovarian cancer	7.05e-06	0.000113	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PIK3CG—ovarian cancer	6.81e-06	0.000109	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.42e-06	0.000103	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PIK3CD—ovarian cancer	5.99e-06	9.59e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.64e-06	9.03e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PIK3CB—ovarian cancer	5.22e-06	8.36e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.92e-06	7.87e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTEN—ovarian cancer	4.51e-06	7.22e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTEN—ovarian cancer	4.25e-06	6.8e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PIK3CA—ovarian cancer	3.18e-06	5.09e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3e-06	4.8e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKT1—ovarian cancer	2.6e-06	4.16e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKT1—ovarian cancer	2.45e-06	3.92e-05	CbGpPWpGaD
